Article

Use to widen: Prescription inserts see extended range in Europe

Fremont, CA-Addition Technology Inc. will double its product line in Europe since it recently received a CE marking for six new sizes of Intacs prescription inserts. The new sizes extend the availability of the inserts in both smaller increments (0.275, 0.325, 0.375, and 0.425 mm) and new sizes (0.21 and 0.23 mm).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
Related Content
KALA Bio completes enrollment of CHASE clinical trial
July 12th 2025

KALA Bio completes enrollment of CHASE clinical trial

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

LIGHTHOUSE study of ATSN-201 expanded to continuous phase 1/2/3 trial following FDA feedback
July 11th 2025

LIGHTHOUSE study of ATSN-201 expanded to continuous phase 1/2/3 trial following FDA feedback

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy
July 10th 2025

Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
July 10th 2025

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

© 2025 MJH Life Sciences

All rights reserved.